unmet
medical
need
AGI is a specialty pharmaceutical company which is focused on the
development and commercialisation of differentiated specialty drug
products to treat unmet medical needs, including conditions which
qualify for Orphan drug status.
In February, 2012, AGI Therapeutics was acquired by Aravis Limited,
a member of the Vidara Therapeutics group of companies. Following
the acquisition, on March 2nd, 2012, AGI de-listed from the Alternative
Investment Market of the London Stock Exchange (AIM) and the Enterprise
Securities Market of the Irish Stock Market (ESM).
AGI will continue to develop and commercialise specialty products. To learn more about Vidara, click on vidararx.com.